1. AB0275 One-Year Treatment Patterns and Healthcare Resource Use Among Patients with Rheumatoid Arthritis Newly Initiating Treatment with Biologic Dmards. (9th June 2015) Authors: Harnett, J.; Gerber, R.; Gruben, D.; Wiederkehr, D.; Mahgoub, E.Y.; Wallenstein, G.; Koenig, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0294 Treatment modes in rheumatoid arthritis: factors influencing patient preference. (12th June 2018) Authors: Taylor, P.C.; Betteridge, N.; Brown, T.M.; Woolcott, J.; Kivitz, A.J.; Zerbini, C.; Whalley, D.; Olayinka-Amao, O.; Chen, C.; Dahl, P.; Ponce de Leon, D.; Gruben, D.; Fallon, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0399 Real-World Experience with Tofacitinib vs Adalimumab (ADA), Etanercept (ETN) and Abatacept (ABA) in Biologic-Experienced Patients with Rheumatoid Arthritis (RA): Data from A US Administrative Claims Database. (15th July 2016) Authors: Harnett, J.; Gerber, R.; Gruben, D.; Koenig, A.; Chen, C. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0137 Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis. (23rd January 2014) Authors: McInnes, I. B.; Kaplan, I.; Boy, M.; Riese, R.; Zuckerman, A.; Gruben, D.; Brosnan, M. J.; Zwillich, S.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0185 Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs - a network meta-analysis. (23rd January 2014) Authors: Vieira, M.C.; Wallenstein, G.V.; Bradley, J.D.; Gruben, D.; Koncz, T.; Zwillich, S.H.; Jansen, J.P. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial. (23rd January 2014) Authors: Genovese, M.; van Vollenhoven, R.; Wilkinson, B.; Wang, L.; Zwillich, S.; Gruben, D.; Benda, B.; Jones, T.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Arthritis. (10th June 2014) Authors: Alten, R.; Strand, V.; Fleischmann, R.; Koncz, T.; Zwillich, S.; Bradley, J.; Gruben, D.; Wilkinson, B.; Krishnaswami, S.; Wallenstein, G. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OP0253 The JAK Inhibitor Tofacitinib Suppresses Synovial JAK1-STAT1 Signalling in Rheumatoid Arthritis. (23rd January 2014) Authors: Boyle, D. L.; Wei, N.; Singhal, A. K.; Rosengren, S.; Kaplan, I.; Soma, K.; Hodge, J.; Luo, Z.; Krishnaswami, S.; Gruben, D.; Zwillich, S. H.; Bradley, J.; Firestein, G. S. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. (1st February 2016) Authors: Harnett, J.; Wiederkehr, D.; Gerber, R.; Gruben, D.; Koenig, A.; Bourret, J. Journal: Journal of medical economics Issue: Volume 19:Number 2(2016) Page Start: 101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. SAT0115 Tofacitinib Versus Biologic Treatments in Patients with Active Rheumatoid Arthritis Who have had an Inadequate Response to Tumour Necrosis Factor Inhibitors - A Network Meta-Analysis. (23rd January 2014) Authors: Vieira, M. C.; Wallenstein, G.; Bradley, J.; Gruben, D.; Koncz, T.; Zwillich, S. H.; Jansen, J. P. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗